Potential value of cassia bark for CFS

Research abstract:

The fruit of Cassia fistula Linn. is a legume, has antioxidant and lots of other medicinal properties. As oxidants are involved in the pathogenesis of chronic fatigue syndrome, the present study was done to evaluate the effect of ethanolic extract of fruit pulp of C. fistula Linn. (EECF) on forced swimming induced chronic fatigue syndrome (CFS).

Albino mice of 25-40 grams were grouped into five groups (n=5). Group A served as naive control and group B served as stress control. Group C received EECF 200 mg/kg and group D received EECF 400 mg/kg respectively. Group E received imipramine 20 mg/kg (standard). All animals were treated with their respective agent orally daily for 7 days.

Except for group A, animals in other groups were subjected to force swimming 6 min daily for 7 days to induce a state of chronic fatigue. Duration of immobility was assessed on day 1st, 3rd, 5th and 7th. Anxiety level (by elevated plus maze and mirrored chamber) and loco-motor activity (by open field test) were assessed 24 h after last force swimming followed by biochemical estimations of oxidative biomarkers in brain homogenate at the end of study.

Treatment with EECF resulted in significant reduction in the duration of immobility, reduced anxiety and increased loco-motor activity. Malondialdehyde level was also reduced and catalase level was increased in the extract treated group and standard group compared to stress control group. The study indicates that EECF has protective effect against experimentally induced CFS.

Evaluation of the effect of ethanolic extract of fruit pulp of Cassia fistula Linn. on forced swimming induced chronic fatigue syndrome in mice. Sarma P, et al. in Res Pharm Sci, 2015 May-Jun; 10(3): 206-213.

 

Posted in News | Tagged , , | Comments Off on Potential value of cassia bark for CFS

Genes disrupt signalling mechanisms in CFS

Research abstract:

Background:
The transient receptor potential (TRP) superfamily in humans comprises
27 cation channels with permeability to monovalent and divalent cations. These channels are widely expressed within humans on cells and tissues and have significant sensory and regulatory roles on most physiological functions. Chronic fatigue syndrome (CFS) is an unexplained disorder with multiple physiological impairments.

Objectives:
The purpose of this study was to determine the role of TRPs in CFS.

Methods:
The study comprised 115 CFS patients (age=48.68 p/m 1.06 years) and 90 nonfatigued controls (age=46.48 p/m 1.22 years). CFS patients were defined according to the 1994 Center for Disease Prevention and Control criteria for CFS. A total of 240 single nucleotide polymorphisms (SNPs) for 21 mammalian TRP ion channel genes (TRPA1, TRPC1, TRPC2, TRPC3, TRPC4, TRPC6, TRPC7, TRPM1, TRPM2, TRPM3, TRPM4, TRPM5, TRPM6, TRPM7, TRPM8, TRPV1, TRPV2, TRPV3, TRPV4, TRPV5, and
TRPV6) were examined via the Agena Biosciences iPLEX Gold assay.
Statistical analysis was performed using the PLINK analysis software.

Results:
Thirteen SNPs were significantly associated with CFS patients compared with the controls. Nine of these SNPs were associated with TRPM3 (rs12682832; P=<0.003, rs11142508; P<0.004, rs1160742; P<0.08, rs4454352; P=<0.013, rs1328153; P=<0.013, rs3763619; P=<0.014, rs7865858; P=<0.021, rs1504401; P=<0041, rs10115622; P=<0.050), while the remainder were associated with TRPA1 (rs2383844; P=<0.040, rs4738202; P=<0.018) and TRPC4 (rs6650469; P=<0.016, rs655207; P=<0.018).

Conclusion:
The data from this pilot study suggest an association between TRP ion channels, predominantly TRPM3 and CFS. This and other TRPs identified may contribute to the etiology and pathomechanism of CFS.

Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients, by Sonya M. Marshall-Gradisnik, Peter Smith, Ekua W. Brenu, Bernd Nilius, Sandra B. Ramos and Donald R. Staines in Immunology and Immunogenetics Insights 2015:7 1-6 [May 10, 2015]

Griffith University Press release  May 11, 2015

Australian Study Pinpoints Possible Gene Issues in Chronic Fatigue Syndrome, by Cort Johnson on May 22, 2015

Posted in News | Tagged , , , , | Comments Off on Genes disrupt signalling mechanisms in CFS

A possible bio-marker for distinguishing inflammation in IBS

Research abstract:

Background: Recent studies demonstrated low-grade inflammation in patients with irritable bowel syndrome (IBS). However, these studies have been relatively small and do not enable examination of this factor in different subtypes of IBS and the possibility of confounding effects of comorbidities that may be associated with inflammatory responses.

Goals: To investigate the association between high-sensitive C-reactive protein (hs-CRP) and the diagnosis of IBS, IBS subtypes, symptoms’ severity, and IBS-associated comorbidities.

Study: This cross-sectional study uses data from a large matched case-control study of IBS subjects and healthy controls (HC). hs-CRP levels were measured in all subjects. IBS diagnosis was determined by Rome III criteria, negative screening blood tests, and normal colonoscopy. Subjects were evaluated for IBS severity and associated pain and psychological comorbidities.

Results: A total of 242 IBS patients and 244 HC were studied. Median hs-CRP levels in the IBS group were significantly higher than in HC (1.80; interquartile range, 0.7 to 4.04 mg/L vs. 1.20, interquartile range, 0.5 to 2.97 mg/L respectively, P<0.006). Levels were highest in IBS-D patients with greater disease severity. Hs-CRP levels mildly correlated with symptoms severity (r=0.169, P=0.009); this correlation was stronger for the IBS-D patients (r=0.27, P=0.006). IBS was a significant independent predictor (P=0.025) for higher hs-CRP levels, whereas other pain and psychological comorbidities were not.

Conclusions: Given these observations of cross-sectional differences in hs-CRP between IBS subtypes and severity, independent of pain and comorbidities, more research is needed to explore a possible role of low-grade inflammation in the pathogenesis and/or clinical presentation of IBS.

High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome, by Hod, Keren MSc; Ringel-Kulka, Tamar MD, MPH; Martin, Christopher F. MSPH; Maharshak, Nitsan MD; Ringel, Yehuda MD in Journal of Clinical Gastroenterology

Posted in News | Tagged , , , , , | Comments Off on A possible bio-marker for distinguishing inflammation in IBS

Post-poliomyelitis syndrome as a possible viral disease

Review abstract:

The review summarizes current concepts on the Post-Polio Syndrome (PPS), a condition that may arise in polio survivors after partial or complete functional recovery followed by an prolonged interval of stable neurologic function. PPS affects 15-20 million people worldwide. Epidemiologic data are reported, together with pathogenic pathways that possibly lead to the progressive degeneration and loss of neuromuscular motor units. As a consequence, polio survivors experience new weakness, generalized fatigue, atrophy of previously unaffected muscles, and physical decline that may culminate in the loss of independent life. Emphasis is given to the possible pathogenic role of persistent poliovirus infection and chronic inflammation.
These factors could contribute to neurological and physical decline in polio survivors. A perspective is then given on novel anti-poliovirus compounds and monoclonal antibodies that have been developed for contributing to the final phases of polio eradication. These agents could also be useful for treating or preventing PPS. Some of these compounds/antibodies are in early clinical development. Finally, current clinical trials for PPS are reported. In this area, the intravenous infusion of normal human immunoglobulins seems both feasible and promising.

Post-poliomyelitis syndrome as a possible viral disease, by Baj A, Colombo M, Headley JL, McFarlane JR, Liethof MA, Toniolo A in Int J Infect Dis. 2015 May 1. pii [Epub ahead of print]

Posted in News | Comments Off on Post-poliomyelitis syndrome as a possible viral disease

TMJ is common in POTS

Research abstract:

AIMS: To explore the point prevalence of painful temporomandibular disorders (TMD) in a well-characterized clinical cohort of postural orthostatic tachycardia syndrome (PoTS) sufferers and to understand the functional and physiologic impact of this comorbidity on the patient.

METHODS: Patients with PoTS were retrospectively recruited from a previous study conducted in a UK hospital setting. Data had previously been collected on several parameters, including sociodemographic, physiologic, and functional. The participants were mailed a highly sensitive (99%) and specific (97%) self-report screening instrument for painful TMD. Simple descriptive statistics with Fisher Exact and Kruskal-Wallis tests were used to examine the data and draw inferences from it.

RESULTS: A total of 36 individuals responded (69% response rate). Just under half (47%) of the sample screened positive for painful TMD.
There was no significant difference between the screening result for TMD or previously reported headaches or joint pain (P < .05). Chronic fatigue syndrome (CFS) was diagnosed by the Fukuda Criteria in 44% of the total sample and in 56% of those with painful TMD. There were no significant differences in physiologic parameters in CFS and TMD. TMD caused a significant decrease in quality of life as measured by the Patient-Reported Outcomes Measurement Information System, Health Assessment Questionnaire (P < .05).

CONCLUSION: TMD are common in patients with PoTS. They have a significant, additional impact on patients’ quality of life and should therefore be screened for at an early stage in PoTS.

Painful Temporomandibular Disorders Are Common in Patients with Postural Orthostatic Tachycardia Syndrome and Impact Significantly upon Quality of Life by J, Durham, C McDonald, L Hutchinson, JL Newton in J Oral Facial Pain Headache 2015 Spring;29(2):152-7

Posted in News | Comments Off on TMJ is common in POTS

ME/CFS – a multisystem disorder

Research abstract:

Background
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, chronic illness that is often disabling. This paper introduces the Chronic Fatigue Initiative, which conducted a large multi-center study to more fully characterize ME/CFS and ultimately to describe and understand the underlying mechanisms and pathogenesis of this illness.

Methods:
A total of 203 patients with ME/CFS (cases) and 202 matched healthy controls (HCs) were enrolled from 5 geographically different expert clinical sites to create a well-characterized population linked to a national biorepository. ME/CFS subjects were compared to a one-to-one matched HC population for analyses of symptoms and illness severity. Cases were further evaluated for frequency and severity of symptoms and symptom clusters, and the effects of illness duration and acute vs. gradual onset.

Results:
This study collected more than 4000 pieces of data from each subject in the study. Marked impairment was demonstrated for cases vs. controls. Symptoms of fatigue were identified, but also, nearly as frequent and severe, were symptoms of cognitive dysfunction, inflammation, pain and autonomic dysfunction. Potential subgrouping strategies were suggested by these identified symptom clusters: sleep, neurocognitive, autonomic, inflammatory, neuroinflammatory, gastrointestinal and endocrine symptoms.

Conclusions
Clearly, ME/CFS is not simply a state of chronic fatigue. These data indicate that fatigue severity is matched by cognitive, autonomic, pain, inflammatory and neuroinflammatory symptoms as the predominant clinical features. These findings may assist in the clarification and validation of case definitions. In addition, the data can aid clinicians in recognizing and understanding the overall illness presentation. Framing ME/CFS as a multisystem disorder may assist in developing therapies targeting the multifaceted domains of illness.

Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/ chronic fatigue syndrome, by N.G. Klimas, G. Ironson, A. Carter, E. Balbin, L. Bateman, D. Felsenstein, S. Levine, D. Peterson, K. Chiu, A. Allen, K. Cunningham, C.G. Gottschalk, M. Fletcher, M. Hornig, C. Canning, A.L. Komaroff in Fatigue Vol.3, #2, pp 75-96
Published online: 24 Apr 2015

More info: Chronic fatigue initiative at Hutchins Family Foundation

Posted in News | Tagged , , , , , , , , , , , , , , , , , | Comments Off on ME/CFS – a multisystem disorder

Defining recovery in children

Research abstract:

Aims:  To describe how recovery from paediatric CFS/ME is defined, how many children recover and how long it takes.

Methods:  We conducted detailed literature searches of MEDLINE, EMBASE, PsycInfo and the Cochrane library, searched trial registration sites, contacted authors if results have not been published and hand searched reference lists. Three categories of search terms were used; paediatric, CFS/ME and recovery.

Inclusion criteria: Randomised controlled trials or observational studies of participants <19 years old with a diagnosis of CFS/ME, related to a Western Health Care system, some measure of recovery (partial or full) reported and the time taken to reach it.

Results: 21 papers were identified. The study populations ranged from 1 to 64 participants, their duration of illness ranged from 3 months to 7 years between studies and also showed great variety within each study. Some studies used a single measurement outcome for recovery, others measured several and some integrated multiple outcomes to formulate one value for recovery.

The recovery rate ranged from 25–100% in those accessing treatment and 4.5–100% in those without specialist care. School attendance was the most common measurement outcome (n = 11), of which 4 of these combined this with at least one other measure. 7 studies measured physical ability as an outcome, 8 used fatigue and 9 measured a global improvement that was either self-rated or qualitatively assessed by an investigator. 2 studies described recovery as no longer fulfilling the diagnostic criteria.

Conclusion: Recovery rates are relatively high in children accessing specialist treatment however, the discrepancies between the measurement outcomes, makes interpretation of recovery rates difficult.

G358 A systematic review to identify the definitions of recovery for paediatric patients with chronic fatigue syndrome (cfs) or myalgic encephalomyelitis (me), by used in studies since 1994, by Y Moore, NME Anderson, E Crawley in Arch Dis Child 2015;100:A146-A147

Posted in News | Tagged , , , , , | Comments Off on Defining recovery in children

The long wait for a breakthrough in CFS

Article

Not over yet

There hasn’t been much good news for patients with the prevalent but
enigmatic disorder chronic fatigue syndrome (also referred to as
myalgic encephalomyelitis). Over decades, research into the
pathophysiology has failed to find convincing evidence of either persistent infection or immunological, endocrine, or metabolic change,  and has rejected simplistic notions of depression (typical or  atypical) or primary sleep disorder.

Several notable “breakthroughs”  have failed independent replication. The most noteworthy is the recent  rise and fall of xenotropic murine leukaemia virus related virus  (XMRV) as the cause, which was ultimately established as a murine DNA  laboratory contaminant.1

Similarly, an exhaustive array of randomised controlled trials seeking curative outcomes from antiviral, immunological, hormonal, antidepressant, and many other therapies have failed to show any benefit over placebo, or failed the replication test.

Where then is the progress?

Firstly, there is reproducible evidence implicating certain infections as a trigger—notably, infectious mononucleosis caused by Epstein-Barr virus, but also infection with other pathogens.2

Secondly, there is clear evidence that a substantial proportion of patients have a coexisting mood disorder, and sometimes a sleep-wake disorder, and that these conditions may exacerbate or perpetuate the illness.3

Thirdly, independent studies using both structural and functional imaging techniques have identified alterations in the brains of patients with chronic fatigue syndrome, implicating the central nervous system as the site of
pathophysiology.4

Fourthly, there is solid evidence from multiple controlled studies that patients can gain control of symptoms and functional improvement through multidisciplinary interventions incorporating graded exercise therapy and cognitive behavioural therapy. These interventions have clearly positive outcomes in systematic reviews and meta-analyses.5 6 7

For instance, the recent Cochrane review of graded exercise therapy5 states that “patients with CFS [chronic fatigue syndrome] may generally benefit and feel less
fatigued following exercise therapy, and no evidence suggests that exercise therapy may worsen outcomes. A positive effect with respect to sleep, physical function and self-perceived general health has been observed.”

How therapy works

Plausibly, graded exercise may reverse a perpetuator in the form of physical deconditioning. However, there is little evidence for loss of aerobic fitness in patients with chronic fatigue syndrome, and limited evidence for improved physical performance after successful graded exercise therapy.8

Instead, graded exercise has been proposed to act by desensitising an exaggerated central nervous system response to the physiological signals associated with exercise.9 In psychological terms, patients may avoid activity because of the prolonged exacerbation of symptoms that follows minor physical activity; this
leads to an understandable conclusion that exercise is harmful or to a
conditioned fear of such activity.10

In this respect, the recent mediation analysis of the outcomes of the PACE trial is of interest.11 This trial compared standard medical care, cognitive behavioural
therapy, graded exercise, and adaptive pacing therapy, concluding that both cognitive behavioural and graded exercise therapy were more effective at reducing fatigue and improving physical disability than standard care or adaptive pacing.12 The mediation analysis suggested that both cognitive behavioural therapy and graded exercise worked by reducing avoidance of activity. This is broadly consistent with findings by others,13 although whether the effect simply relates to the behavioural change itself (that is, exercise) or reconditioning of
the associated fear of activity remains unclear.

In addition, a substantial proportion of patients do not avoid activity but have
repeated boom-bust cycles of overactivity when feeling relatively well (the boom) followed by reduced activity when symptoms are exacerbated thereafter (the bust). These data argue for a personalised approach to both therapies.

Cognitive behavioural therapy for patients with chronic fatigue syndrome is based on the premise that inappropriate cognitive attributions (thinking patterns) and behaviours help perpetuate symptoms. It seeks to alter these attributions and modify the associated behaviour, targeting activity patterns and sleep-wake behaviours.

For example, although primary sleep disorders do not explain chronic fatigue syndrome,14 patients typically report that their night-time sleep is unrefreshing, and as fatigue is the dominant symptom, patients may consider that increased sleep will relieve symptoms and aid recovery. This idea commonly leads to frequent daytime naps and a delayed sleep-wake cycle.

Prospects for cure

There has been recent contention about the possibility of cure after graded exercise and cognitive behavioural therapy. An analysis of the PACE trial suggested cure was possible, but recovery outcomes were defined post hoc using population norms with generous thresholds (such as the population mean plus one standard deviation for self reported fatigue).15

This analysis was criticised because of the limited assesments and less than full restoration of health,16 leading to a recommendation that trials use more accurate outcomes (such as clinically relevant improvement) defined in advance and capturing a broad based return to health with assessments of fatigue and function.

Trialists must also consider patients’ perceptions of their recovery.17 In this context, the increase in volume of grey matter associated with clinical response to cognitive behavioural therapy, as reported in one study,  needs further investigation.18  Even with the unduly liberal designation of recovery, less than one quarter of patients “recovered” in the PACE trial.

What then of the long awaited breakthrough? As is often the case in medical research, progress is predominantly made in modest increments not breakthroughs. The evidence for graded exercise and cognitive behavioural therapy is already clear, so this treatment should be made widely available. The next increments are to find ways to increase the symptom relief and functional improvement achieved by these treatments and to identify factors predicting clinically relevant improvement and non-response in order to increase the proportion of patients who benefit.

The long wait for a breakthrough in chronic fatigue syndrome, by Prof Andrew R Lloyd,  Prof Jos W Van der Meer in BMJ 2015; 350 doi:  (Published 05  May 2015)

Many people have written letters challenging aspects of Lloyd and Van der Meer’s article: Rapid responses

Provenance and peer review: Commissioned; not externally peer reviewed.

References

1. Van Kuppeveld FJ, van der Meer JW. XMRV and CFS—the sad end of a
story. Lancet2012;379:e27-8.
2. Hickie I, Davenport T, Wakefield D, et al. Post-infective and
chronic fatigue syndromes precipitated by viral and non-viral
pathogens: prospective cohort study. BMJ2006;333:575.
3. Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome.
Lancet2006;367:346-55.
4. Tanaka M, Ishii A, Watanabe Y. Neural mechanisms underlying chronic
fatigue. Rev Neurosci2013;24:617-28.
5. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy
for chronic fatigue syndrome. Cochrane Database Syst
Rev2015;2:CD003200.
6. Reid S, Chalder T, Cleare A, Hotopf M, Wessely S. Chronic fatigue
syndrome. BMJ 2000;320:292-6.
7. Knight SJ, Scheinberg A, Harvey AR. Interventions in pediatric
chronic fatigue syndrome/myalgic encephalomyelitis: a systematic
review. J Adolesc Health2013;53:154-65.
8. Moss-Morriss R, Sharon C, Tobin R, Baldi JC. A randomized
controlled graded exercise trial for chronic fatigue syndrome:
outcomes and mechanisms of change. J Health Psychol2005;10:245-59.
9. Nijs J, Meeus M, Van Oosterwijck J, et al. In the mind or the
brain? Scientific evidence for central sensitisation in chronic
fatigue syndrome. Eur J Clin Invest2011;42:203-11.
10. Clark LV, White PD. The role of deconditioning and therapeutic
exercise in chronic fatigue syndrome (CFS). J Mental
Health2005;14:237-52.
11. Chalder T, Goldsmith KA, White PD, Sharpe M, Pickles AR.
Rehabilitative therapies for chronic fatigue syndrome: a secondary
mediation analysis of the PACE trial. Lancet Psychiatry2015;2:141-52.
12. White PD, Goldsmith KA, Johnson AL, et al. Comparison of adaptive
pacing therapy, cognitive behaviour therapy, graded exercise therapy,
and specialist medical care for chronic fatigue syndrome (PACE): a
randomised trial. Lancet2011;377:823-36.
13. Wiborg JF, Knoop H, Prins JB, Bleijenberg G. Does a decrease in
avoidance behavior and focusing on fatigue mediate the effect of
cognitive behavior therapy for chronic fatigue syndrome? J Psychosom
Res2011;70:306-10.
14. Jackson ML, Bruck D. Sleep abnormalities in chronic fatigue
syndrome/myalgic encephalomyelitis: a review. J Clin Sleep
Med2012;8:719-28.
15. White PD, Goldsmith K, Johnson AL, Chalder T, Sharpe M. Recovery
from chronic fatigue syndrome after treatments given in the PACE
trial. Psychol Med2013;43:2227-35.
16. Kindlon T, Baldwin A. Response to: reports of recovery in chronic
fatigue syndrome may present less than meets the eye. Evid Based
Mental Health2014. doi:10.1136/eb-2014-101961.
17. Adamowicz JL, Caikauskaite I, Friedberg F. Defining recovery in
chronic fatigue syndrome: a critical review. Qual Life Res2014;23:2407-16.
18. De Lange FP, Koers A, Kalkman JS, et al. Increase in prefrontal
cortical volume following cognitive behavioural therapy in patients
with chronic fatigue syndrome. Brain2008;131:2172-80.

 

Posted in News | Comments Off on The long wait for a breakthrough in CFS

Differences found in CFS experience in UK & USA

Research abstract:

Few studies have compared symptomatology and functional differences experienced by patients with chronic fatigue syndrome (CFS) across cultures. The current study compared patients with CFS from the United States (US) to those from the United Kingdom (UK) across areas of functioning, symptomatology, and illness onset characteristics.

Individuals in each sample met criteria for CFS as defined by Fukuda et al. (1994). These samples were compared on two measures of disability and impairment, the DePaul Symptom Questionnaire (DSQ) and the Medical outcomes study 36-item short-form health survey (SF-36).

Results revealed that the UK sample was significantly more impaired in terms of mental health and role emotional functioning, as well as specific symptoms of pain, neurocognitive difficulties, and immune manifestations. In addition, the UK sample was more likely to be working rather than on disability.

Individuals in the US sample reported more difficulties falling asleep, more frequently reported experiencing a sudden illness onset (within 24 hours), and more often reported that the cause of illness was primarily due to physical causes.

These findings suggest that there may be important differences in illness characteristics across individuals with CFS in the US and the UK, and this has implications for the comparability of research findings across these two countries.

A Cross Cultural Comparison of Disability and Symptomatology Associated with CFS, by Maria Zdunek, Leonard A. Jason, Meredyth Evans, Rachel Jantke, Julia L. Newton in International Journal of Psychology and Behavioral Sciences, May 2015

Posted in News | Tagged , , , , | Comments Off on Differences found in CFS experience in UK & USA

Crowdfunded study into biomarkers for people with severe ME/CFS

The ME/CFS Crowdfunding Campaign is a new initiative to promote crowdfunding campaigns for ME/CFS research and grow the crowdfunding community. More info from the Facebook page including regular updates on the current campaigns.

The first crowdfund campaign is – END ME/CFS’s ‘Big Data’ study for biomarkers in severely ill patients.

This is a hugely exciting study. The END ME/CFS board includes three Nobel laureates and is headed by world-famous geneticist Dr Ron Davis, whose son is a severely ill patient. The researchers are looking for molecular biomarkers for ME/CFS and they’re going to do this by looking where the disease is burning brightest: in the most severely ill, housebound and bedbound patients. And they’ll bring a powerful ‘big data’ approach by taking samples of blood, saliva, sweat, urine and feces, running a sophisticated and comprehensive battery of tests, and using powerful data analysis methods to find those biomarkers.

They want to study 40 patients but they’ve set an initial, interim target to enable them to get the study underway immediately: 15 patients at a cost of $25,000 each, for a highly achievable goal of  $375,000 (£240,000, €330,000). There have already been some very generous donations which we will give updates about soon, so that goal has already got a lot closer!

To donate: Open Medicine Foundation

Posted in News | Tagged , , , , | Comments Off on Crowdfunded study into biomarkers for people with severe ME/CFS